Citius Pharmaceuticals Reports Passive Dilution in Citius Oncology Stake to 71%

Citius Pharmaceuticals, Inc. filed Amendment No. 4 to its Schedule 13D on June 4, 2026, regarding its investment in Citius Oncology, Inc. (CTOR). The filing reports that Citius Pharmaceuticals continues to hold 66,049,615 shares of Common Stock. While the absolute number of shares held by the reporting person remained unchanged, their beneficial ownership percentage decreased to approximately 71.0%. This decrease from the previously reported level is due solely to a material increase in the Issuer's total outstanding shares, which reached 92,981,204 as of May 14, 2026. The filing notes that additional shares from a warrant exercise on May 6, 2026, are currently held in abeyance due to beneficial ownership limitations and are not included in the current outstanding share count. Citius Pharmaceuticals maintains sole voting and dispositive power over its 66,049,615 shares. No new acquisitions or dispositions of shares by the reporting person occurred during this period.